Related Experiment Video

Updated: May 19, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The in vitro anticoagulant effect of rivaroxaban in children

C Attard1, P Monagle, D Kubitza

  • 1Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria 3052, Australia.

Thrombosis Research
|August 14, 2012
PubMed

Insights

Rivaroxaban showed consistent anticoagulant effects across pediatric age groups in vitro. Further in vivo studies are needed to confirm its dose-response consistency in children.

Area of Science:

  • Pharmacology
  • Pediatric Hematology
  • Thrombosis Research

Background:

  • Current anticoagulation in children is suboptimal, necessitating frequent monitoring and dose adjustments.
  • Novel anticoagulants targeting specific coagulation factors offer potential improvements.
  • Rivaroxaban, an oral direct Factor Xa inhibitor, has shown promise due to its favorable pharmacokinetic profile.

Purpose of the Study:

  • To investigate the age-specific in vitro anticoagulant effect of rivaroxaban in pediatric populations.
  • To evaluate the consistency of rivaroxaban's anticoagulant activity across different pediatric age groups.

Main Methods:

  • Created age-specific plasma pools from neonates to adults (28 days to adult).
  • Spiked plasma pools with varying concentrations of rivaroxaban (0-500 ng/ml).
  • Assessed rivaroxaban's effect using prothrombin time (PT), activated partial thromboplastin time (APTT), anti-Factor Xa assays, and thrombin generation assays.

Main Results:

  • No significant differences in rivaroxaban's anticoagulant effect were observed across the studied pediatric age groups in vitro.
  • The in vitro data suggest a consistent response to rivaroxaban regardless of age.

Conclusions:

  • In vitro findings indicate potential for consistent rivaroxaban efficacy across pediatric age ranges.
  • Further in vivo studies are essential to validate the dose-response relationship and confirm safety and efficacy in children.
Abstract

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...